Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor

Completed

• Conditions: Cystic Fibrosis Homozygous for Phe 508 Del CFTR; Glucose Intolerance or Newly Diagnosis Diabetes
• Interventions: Drug: Lumacaftor-Ivacaftor treatment

• Registration Number: NCT03512119
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years.

At the physiopathology level, insulin secretion is determinant in the glucose tolerance abnormalities in CF. Indeed insulin secretion is dependent of the CFTR activity at the beta cell surface and inhibition of CFTR leads to a decrease in insulin secretion.

Recently, the combination of the lumacaftor, a CFTR corrector, with Ivacaftor, a CFTR potentiator, was studied in patient with CF homozygous for the Phe508 del CFTR mutation patients and showed an improvement of the respiratory state in comparison with the placebo group.

These data suggests that lumacaftor in combination with ivacaftor in targeting CFTR action may have an early impact on the insulin-secretion and consequently on the glucose tolerance.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-11
• Study First Submitted: 2018-01-15
• Study First Submitted QC: 2018-04-18
• Study First Posted: 2018-04-30
• Primary Completion: 2019-04-10
• Study Completion: 2019-04-10
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-23
• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• patients with CF homozygous for the Phe508del CFTR mutation aged 12 years and over
• Combined Lumacaftor-Ivacaftor treatment scheduled or already started
• glucose intolerance in OGTT (ADA criteria) or newly diabetes diagnosed at the OGTT (ADA criteria) or diabetic patients with insulin requirement ≤ 0.3 unit / kg / day or without insulin treatment
• signed informed consent of patient and of one parent OR legal representative for minor subject

Exclusion Criteria

• hypersensitivity to the active substances or to any of the excipients of Lumactfor -Ivacaftor
• lung and/or liver transplant patient
• Known diabetes with insulin treatment > 0.3 unit / kg / day
• patient pregnant or wishing to pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patient	Lumacaftor-Ivacaftor treatment	Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes

Primary Outcome Measures

Name	Time	Method
Measure of 2 hours plasma glucose value (mmol/l) of OGTT, change from baseline at one year of Lumacaftor-Ivacaftor treatment	Day 0 (traitement beginning) and year 1

Secondary Outcome Measures

Name	Time	Method
Mean glucose value per day and 2 h after meal (mg/dl)	Day 0 (traitement beginning) and year 1
HOMA -R , HOMA-S	Day 0 (traitement beginning) and year 1
(BMI) body mass index	Day 0 (traitement beginning) and year 1
Weight (Kg) maximum weight never reached	Day 0 (traitement beginning) and year 1
Fasting and one hour glucose value of OGTT (mmol/l)	Day 0 (traitement beginning) and year 1
Duration in hypoglycemic area [hypo CGM = 2 consecutive values below 3.3 mmol/l - % of time spent]	Day 0 (traitement beginning) and year 1
Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)	Day 0 (traitement beginning) and year 1
Daily insulin doses (UI/day)	Day 0 (traitement beginning) and year 1
Duration in hyperglycemic area [for glucose value higher than 7.7 mmol/l, % time /24h]	Day 0 (traitement beginning) and year 1	Number hypoglycaemic events (below 3.3mmol/L, from midnight to 6 am) Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)
HbA1c (mmol/l and %)	Day 0 (traitement beginning) and year 1
Number of cures of antibiotics IV and per os /year and interval between 2 cures (week)	Day 0 (traitement beginning) and year 1
C peptide and insulin values at T0, 1 , 2 hours of OGTT (µg/l)	Day 0 (traitement beginning) and year 1
Albumin and Pre albumin (g/l)	Day 0 (traitement beginning) and year 1
O2 saturation (%)	Day 0 (traitement beginning) and year 1
Glucose, insulin and C peptide AUC of OGTT (µU/L)	Day 0 (traitement beginning) and year 1
Number hypoglycaemic events (below 3.3mmol/L, from midnight to 6 am)	Day 0 (traitement beginning) and year 1	Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)
FEV1, Vital Capacity (VC) (L and %)	Day 0 (traitement beginning) and year 1

Trial Locations

Locations (13)

Centre Hospitalier Universitaire d'Angers; 🇫🇷 Angers, France

Hôpitaux Universitaires de Strasbourg; 🇫🇷 Strasbourg, Alsace, France

Hôpital Renée Sabran; 🇫🇷 Giens, France

Hôpital Bretonneau - CHRU de Tours; 🇫🇷 Tours, France

Centre Hospitalier Lyon Sud; 🇫🇷 Lyon, France

Hôpital FOCH; 🇫🇷 Suresnes, France

Hôpital NORD - Assistance Publique Hôpitaux de Marseille; 🇫🇷 Marseille, France

Clinique "Mucoviscidose" Presqu'île de Perharidy; 🇫🇷 Roscoff, France

Hôpital Robert Debré; 🇫🇷 Paris, France

Hôpital Arnaud de Villeneuve; 🇫🇷 Montpellier, France

American Memorial Hospital; 🇫🇷 Reims, France

Hôpital Charles Nicolle; 🇫🇷 Rouen, France

Hôpital de Clocheville - CHRU de Tours; 🇫🇷 Tours, France